en
Scientific article
English

Anti-CD79 antibody induces B cell anergy that protects against autoimmunity

Published inThe Journal of immunology, vol. 192, no. 4, p. 1641-1650
Publication date2014
Abstract

B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy.

Keywords
  • Animals
  • Antibodies, Monoclonal/immunology
  • Antigens, CD79/immunology
  • Autoimmune Diseases/prevention & control
  • Autoimmunity/immunology
  • B-Lymphocytes/immunology
  • Clonal Anergy/immunology
  • Female
  • Lymphocyte Activation/immunology
  • Lymphocyte Count
  • Lymphocyte Depletion
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred DBA
  • Mice, Knockout
Citation (ISO format)
HARDY, Ian R et al. Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. In: The Journal of immunology, 2014, vol. 192, n° 4, p. 1641–1650. doi: 10.4049/jimmunol.1302672
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0022-1767
670views
0downloads

Technical informations

Creation05/08/2014 1:44:00 PM
First validation05/08/2014 1:44:00 PM
Update time03/14/2023 9:12:26 PM
Status update03/14/2023 9:12:25 PM
Last indexation01/16/2024 9:57:29 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack